Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
2020 · ESMO Open · 51 citations
https://doi.org/10.1136/esmoopen-2020-000942
C
Chadi Nabhan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
280
Papers
2.3K
Citations
25
h-index
49
i10-index
Chadi Nabhan is an academic researcher. The author has contributed to research in topics: Prostate Cancer Treatment and Research & PARP inhibition in cancer therapy & Cancer Immunotherapy and Biomarkers. The author has an h-index of 25, co-authored 238 publications.
ORCID: 0000-0002-4316-7826Papers by this author
worksPhase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
2012 · British Journal of Cancer · 17 citations
https://doi.org/10.1038/bjc.2012.312
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)
2020 · EClinicalMedicine · 7 citations
https://doi.org/10.1016/j.eclinm.2020.100693
Segmented regression analysis (all chemotherapy patients).
2020 · Figshare · 0 citations
https://doi.org/10.1371/journal.pone.0234541.s001
FIGURE 4 from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies
2024 · 0 citations
https://doi.org/10.1158/2767-9764.25934119
Data from Pan-Cancer Interrogation of B7-H3 (<i>CD276</i>) as an Actionable Therapeutic Target Across Human Malignancies
2024 · 0 citations
https://doi.org/10.1158/2767-9764.c.7260484
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat